To kick off the MS Global Healthcare Conference, onSeptember 14, Risinger and Harrison hosted former FDACommissioner Dr. Scott Gottlieb to discuss COVID vaccines, antibodies, and FDA considerations. Dr. Gottlieb is reasonably confident that one or more COVID vaccines will be successful. He believes the Phase 1 and 2 data published thus far has demonstrated relatively robust immunogenicity and also the…
Morgan Stanley Healthcare Conference: Dr. Scott Gottlieb
A financial market resource for the every-day investor and trader.
-
Morgan Stanley: Mid-Cycle Update
Seth Golden, , Research Reports, 0
Mid-Cycle Brings More Risk than Reward We’re entering mid-cycle faster than normal. Rate of change on growth & policy...
-
Will Markets Give Investors Another Dip to Buy?
Seth Golden, , Research Reports, 0
Over the last 2-3 weeks, Finom Group has outlined our market outlook during the bear market saga, by forecasting...
-
Markets Look Beyond the Wall of Worry
Seth Golden, , Research Reports, 0
The market fell last week and snapped a 3-week win streak after the major indices danced around record highs....
-
A Positive October, To-Date And a 6-Month Win Streak To Be?
Seth Golden, , Research Reports, 0
Good weekend Finom Group investors and traders! This is our “off-reporting” weekend. Please take some time to read our...
-
A Macro-Market Mashup
Seth Golden, , Research Reports, 0
Good weekend to all Finom Group members! During our off-reporting weekend, please find the following reporting from RBC Capital...
-
Planting New Positions For Future Profit Harvests
Seth Golden, , Research Reports, 0
Welcome back Finom Group traders and investors! Two weeks ago the markets struggled, but still managed to eek out...
-
Quarterly Update For Golden Capital Portfolio: Tesla Remains In Focus After Quick Profits
Seth Golden, , Research Reports, 0
Golden Capital Portfolio continues to outperform the benchmark S&P 500 Return On Invested Capital year-to-date. In my most recent...
-
Recent Articles
Featured Products
- JPM Market Recap $0.00
- JPM Research Note $0.00
- JP Morgan Market Volatility Report $0.00